SlideShare uma empresa Scribd logo
1 de 51
DENGUE PRESENTED BY: NOR AINI BINTI MOHAMAD NADIAH BINTI MOHD NASIR SHARIFAH MAISARAH BINTI SYED OTHMAN SEMINAR PRESENTATION INFECTION IN   CHILDREN
[object Object]
[object Object],[object Object]
Introduction   ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
 
Epidemiology  ,[object Object],[object Object],[object Object]
 
 
Mode of transmission ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
 
WHO DENGUE CLASSIFICATION ,[object Object],[object Object]
Dengue Virus Infection asymptomatic symptomatic Undifferentiated fever Dengue fever syndrome Dengue   haemorrhagic   fever Without haemorrhage With unusual haemorrhage No shock Dengue shock Syndrome Dengue fever (DF) Dengue Haemorrhagic Fever (DHF)
CASE DEFINITION FOR DENGUE FEVER ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CASE DEFINITION FOR DENGUE SHOCK SYNDROME ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Grade 1 Fever with constitutional symptoms. A positive Hess test. Grade 2 Spontaneous bleeding (skin ± other bleeds) in addition to manifestations of grade 1 Grade 3 Circulatory failure (rapid weak pulse, pulse pressure < 20mmHg) but systolic BP still normal Grade 4 Profound shock (hypotension, undetectable blood pressure and heart rate) WHO Grading Of  DHF/DSS
Limitation of WHO classification ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CLINICAL COURSE OF DENGUE INFECTION ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
 
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],sweat Restlessness Cool extrimities Prolong capillary time Pulse rate increase Diastolic blood pressure increase Pulse pressure narrow Abdominal pain Persistent vomitting Altered concious level Mucosal bleed Tender enlarged liver Pleural effusion, ascites
[object Object],[object Object],[object Object],[object Object]
ONSET OF DEFERVESCENCE USUALLY OCCURS BETWEEN DAY 3 AND DAY 5 OF ILLNESS
 
 
Increase in vascular permeability Leads to leakage of plasma to extravascular compartment Haemoconcentration (> 20%) and hypovolaemic shock Hypovolemia lead to reflex tachycardia and generalized  vasoconstriction   due to increase sympathetic output
Clinical manifestation of vasoconstriction ,[object Object],[object Object],↓↓  urine output ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],tachypnoea  ,[object Object],[object Object],[object Object]
The pathogenetic mechanism responsible for the increased vascular permeability in DHF/DSS is not known Abnormal immune response involving the production of cytokines or chemokines, activation of T-lymphocytes and disturbances of haemostatic system are the major changes seen in DHF.  Secondary infection with a heterotypic dengue virus is associated with increased risk of developing DHF. It is believed to be due to the  antibodydependent enhancement phenomenon.
antibodydependent enhancement phenomenon
infected with dengue develop an immune response to that dengue subtype produced specific antibodies to that subtype specific surface proteins that prevents the virus from binding to macrophage cells and gaining entry another subtype of dengue virus infects the individual virus will activate the immune system to attack it as if it was the first subtype The antibodies bind to the surface proteins but do not inactivate the virus.  The immune response attracts numerous macrophages, which the virus proceeds to infect because it has not been inactivated viral infection much more acute The body releases cytokines that cause the endothelial tissue to become permeable which results in DHF and fluid loss from the blood vessels.
PRINCIPLES OF  MANAGEMENT
Ambulatory monitoring of suspected dengue : ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
Indication for hospitalization: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ICU admission indications: ,[object Object],[object Object]
Monitoring of Suspected Dengue Patients in Wards  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Investigations ,[object Object],[object Object],[object Object],[object Object]
Management of the Acute Phase  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Physiologic status assesment: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
[object Object],[object Object],[object Object]
Bleeding: signs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Management of the Convalescent Phase ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
Discharge Criteria for Hospitalized Patients ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Mais conteúdo relacionado

Mais procurados

Understanding dengue
Understanding dengueUnderstanding dengue
Understanding dengue
Reynel Dan
 
Dengue haemorrhagic fever diagnosis & management
Dengue haemorrhagic fever diagnosis & managementDengue haemorrhagic fever diagnosis & management
Dengue haemorrhagic fever diagnosis & management
Suneth Weerarathna
 
DENGUE FEVER
DENGUE FEVERDENGUE FEVER
DENGUE FEVER
icsp
 

Mais procurados (20)

Dengue
Dengue Dengue
Dengue
 
Dengue fever- a medical study ( definition, management ,prevention ,risks ,pa...
Dengue fever- a medical study ( definition, management ,prevention ,risks ,pa...Dengue fever- a medical study ( definition, management ,prevention ,risks ,pa...
Dengue fever- a medical study ( definition, management ,prevention ,risks ,pa...
 
Rheumatic fever
Rheumatic  feverRheumatic  fever
Rheumatic fever
 
Understanding dengue
Understanding dengueUnderstanding dengue
Understanding dengue
 
Enteric Fever by Dr. Sookun Rajeev Kumar
Enteric Fever by Dr. Sookun Rajeev KumarEnteric Fever by Dr. Sookun Rajeev Kumar
Enteric Fever by Dr. Sookun Rajeev Kumar
 
Dengue Fever
 Dengue Fever Dengue Fever
Dengue Fever
 
Dengue
DengueDengue
Dengue
 
Dengue haemorrhagic fever diagnosis & management
Dengue haemorrhagic fever diagnosis & managementDengue haemorrhagic fever diagnosis & management
Dengue haemorrhagic fever diagnosis & management
 
Dengue In Children
Dengue In ChildrenDengue In Children
Dengue In Children
 
61738813 case-study-rheumatic
61738813 case-study-rheumatic61738813 case-study-rheumatic
61738813 case-study-rheumatic
 
DENGUE FEVER
DENGUE FEVERDENGUE FEVER
DENGUE FEVER
 
Dengue fever
Dengue feverDengue fever
Dengue fever
 
dengue
denguedengue
dengue
 
Dengue fever slide
Dengue fever slideDengue fever slide
Dengue fever slide
 
Rickettsial diseases
Rickettsial diseasesRickettsial diseases
Rickettsial diseases
 
Fever lecture note
Fever lecture noteFever lecture note
Fever lecture note
 
Dengue
DengueDengue
Dengue
 
Dengue fever
Dengue fever Dengue fever
Dengue fever
 
Dengue Fever
Dengue FeverDengue Fever
Dengue Fever
 
Dengue
DengueDengue
Dengue
 

Destaque (14)

8. all
8. all8. all
8. all
 
7. iddm1
7. iddm17. iddm1
7. iddm1
 
8. Acute Lymphoblastic Leukemia
8. Acute Lymphoblastic Leukemia8. Acute Lymphoblastic Leukemia
8. Acute Lymphoblastic Leukemia
 
3. nephrotic syndrome
3. nephrotic syndrome3. nephrotic syndrome
3. nephrotic syndrome
 
4. complex febrile fit
4. complex febrile fit4. complex febrile fit
4. complex febrile fit
 
5. PDA
5. PDA5. PDA
5. PDA
 
Meeting 4 reservation letter (22120579)
Meeting 4 reservation letter (22120579)Meeting 4 reservation letter (22120579)
Meeting 4 reservation letter (22120579)
 
6. age
6. age6. age
6. age
 
3.chronic infection
3.chronic infection3.chronic infection
3.chronic infection
 
Disorders of puberty.pptx 2
Disorders of puberty.pptx 2Disorders of puberty.pptx 2
Disorders of puberty.pptx 2
 
Fever with Rash
Fever with RashFever with Rash
Fever with Rash
 
10. asthma
10. asthma10. asthma
10. asthma
 
6. Acute Gastroenteritis
6. Acute Gastroenteritis6. Acute Gastroenteritis
6. Acute Gastroenteritis
 
2. fever with rash
2. fever with rash2. fever with rash
2. fever with rash
 

Semelhante a 9.dengue seminar

Dengue Fever – Newer Insights.pptx
Dengue Fever – Newer Insights.pptxDengue Fever – Newer Insights.pptx
Dengue Fever – Newer Insights.pptx
Mudreka3
 

Semelhante a 9.dengue seminar (20)

Epidemiology &amp;prevention of dengue
Epidemiology &amp;prevention of dengueEpidemiology &amp;prevention of dengue
Epidemiology &amp;prevention of dengue
 
dengue diagnosis and management
dengue diagnosis and managementdengue diagnosis and management
dengue diagnosis and management
 
The dengue syndrome_Vighnesh D
The dengue syndrome_Vighnesh DThe dengue syndrome_Vighnesh D
The dengue syndrome_Vighnesh D
 
Dengue & It's Management in Bangladesh
Dengue & It's Management in BangladeshDengue & It's Management in Bangladesh
Dengue & It's Management in Bangladesh
 
Dengue diagnosis, treatment, prevention and control
Dengue diagnosis, treatment, prevention and controlDengue diagnosis, treatment, prevention and control
Dengue diagnosis, treatment, prevention and control
 
Dengue 1
Dengue 1Dengue 1
Dengue 1
 
Dengue Fever – Newer Insights.pptx
Dengue Fever – Newer Insights.pptxDengue Fever – Newer Insights.pptx
Dengue Fever – Newer Insights.pptx
 
Dengue in children (F) - Copy.ppt
Dengue in children (F) - Copy.pptDengue in children (F) - Copy.ppt
Dengue in children (F) - Copy.ppt
 
Dengue Syndrome by Dr Faisal Ahmed Abbas
Dengue Syndrome by Dr Faisal Ahmed AbbasDengue Syndrome by Dr Faisal Ahmed Abbas
Dengue Syndrome by Dr Faisal Ahmed Abbas
 
Dengue and chickungunya
Dengue and chickungunyaDengue and chickungunya
Dengue and chickungunya
 
Dengue
DengueDengue
Dengue
 
Dengue virus
Dengue virusDengue virus
Dengue virus
 
dengue virus.pptx
dengue virus.pptxdengue virus.pptx
dengue virus.pptx
 
Dengue
DengueDengue
Dengue
 
latest Dengue.pptx
latest Dengue.pptxlatest Dengue.pptx
latest Dengue.pptx
 
Dengue management
Dengue managementDengue management
Dengue management
 
denguefever-160329120436.pptx
denguefever-160329120436.pptxdenguefever-160329120436.pptx
denguefever-160329120436.pptx
 
Dengue Fever.ppt
Dengue Fever.pptDengue Fever.ppt
Dengue Fever.ppt
 
NATIONAL GUIDELINE OF DENGUE.pptx
NATIONAL GUIDELINE OF DENGUE.pptxNATIONAL GUIDELINE OF DENGUE.pptx
NATIONAL GUIDELINE OF DENGUE.pptx
 
Pediatric dengue management - Dr. Arunkumar, MD(Paed)
Pediatric dengue management - Dr. Arunkumar, MD(Paed)Pediatric dengue management - Dr. Arunkumar, MD(Paed)
Pediatric dengue management - Dr. Arunkumar, MD(Paed)
 

Mais de Whiteraven68 (12)

10. asthma
10. asthma10. asthma
10. asthma
 
3. nephrotic syndrome
3. nephrotic syndrome3. nephrotic syndrome
3. nephrotic syndrome
 
4. Complex Febrile Fit
4. Complex Febrile Fit4. Complex Febrile Fit
4. Complex Febrile Fit
 
3. Nephrotic Syndrome
3. Nephrotic Syndrome3. Nephrotic Syndrome
3. Nephrotic Syndrome
 
10. ac. diarrhoea, vomiting & rec abd pain
10. ac. diarrhoea, vomiting & rec abd pain10. ac. diarrhoea, vomiting & rec abd pain
10. ac. diarrhoea, vomiting & rec abd pain
 
7.congenital heart dss
7.congenital heart dss7.congenital heart dss
7.congenital heart dss
 
5. bleeding disorder
5. bleeding disorder5. bleeding disorder
5. bleeding disorder
 
Congenital adrenal hyperplasia
Congenital adrenal hyperplasiaCongenital adrenal hyperplasia
Congenital adrenal hyperplasia
 
Normal puberty
Normal pubertyNormal puberty
Normal puberty
 
4. Convulsive disorder
4. Convulsive disorder4. Convulsive disorder
4. Convulsive disorder
 
8. Nephrotic Syndrome & AcuteGlomerularNephritis
8. Nephrotic Syndrome & AcuteGlomerularNephritis8. Nephrotic Syndrome & AcuteGlomerularNephritis
8. Nephrotic Syndrome & AcuteGlomerularNephritis
 
1. Acute Resp dzs
1. Acute Resp dzs1. Acute Resp dzs
1. Acute Resp dzs
 

9.dengue seminar

  • 1. DENGUE PRESENTED BY: NOR AINI BINTI MOHAMAD NADIAH BINTI MOHD NASIR SHARIFAH MAISARAH BINTI SYED OTHMAN SEMINAR PRESENTATION INFECTION IN CHILDREN
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.  
  • 7.
  • 8.  
  • 9.  
  • 10.
  • 11.  
  • 12.  
  • 13.
  • 14. Dengue Virus Infection asymptomatic symptomatic Undifferentiated fever Dengue fever syndrome Dengue haemorrhagic fever Without haemorrhage With unusual haemorrhage No shock Dengue shock Syndrome Dengue fever (DF) Dengue Haemorrhagic Fever (DHF)
  • 15.
  • 16.
  • 17.
  • 18. Grade 1 Fever with constitutional symptoms. A positive Hess test. Grade 2 Spontaneous bleeding (skin ± other bleeds) in addition to manifestations of grade 1 Grade 3 Circulatory failure (rapid weak pulse, pulse pressure < 20mmHg) but systolic BP still normal Grade 4 Profound shock (hypotension, undetectable blood pressure and heart rate) WHO Grading Of DHF/DSS
  • 19.
  • 20.
  • 21.
  • 22.  
  • 23.  
  • 24.
  • 25.
  • 26. ONSET OF DEFERVESCENCE USUALLY OCCURS BETWEEN DAY 3 AND DAY 5 OF ILLNESS
  • 27.  
  • 28.  
  • 29. Increase in vascular permeability Leads to leakage of plasma to extravascular compartment Haemoconcentration (> 20%) and hypovolaemic shock Hypovolemia lead to reflex tachycardia and generalized vasoconstriction due to increase sympathetic output
  • 30.
  • 31. The pathogenetic mechanism responsible for the increased vascular permeability in DHF/DSS is not known Abnormal immune response involving the production of cytokines or chemokines, activation of T-lymphocytes and disturbances of haemostatic system are the major changes seen in DHF. Secondary infection with a heterotypic dengue virus is associated with increased risk of developing DHF. It is believed to be due to the antibodydependent enhancement phenomenon.
  • 33. infected with dengue develop an immune response to that dengue subtype produced specific antibodies to that subtype specific surface proteins that prevents the virus from binding to macrophage cells and gaining entry another subtype of dengue virus infects the individual virus will activate the immune system to attack it as if it was the first subtype The antibodies bind to the surface proteins but do not inactivate the virus. The immune response attracts numerous macrophages, which the virus proceeds to infect because it has not been inactivated viral infection much more acute The body releases cytokines that cause the endothelial tissue to become permeable which results in DHF and fluid loss from the blood vessels.
  • 34. PRINCIPLES OF MANAGEMENT
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.  
  • 47.
  • 48.
  • 49.
  • 50.
  • 51.